As Biotechnology companies, AgeX Therapeutics Inc. (NYSEAMERICAN:AGE) and XBiotech Inc. (NASDAQ:XBIT) are our subject to contrast. And more specifically their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AgeX Therapeutics Inc.||1.54M||94.99||10.40M||-0.21||0.00|
Table 1 demonstrates AgeX Therapeutics Inc. and XBiotech Inc.’s top-line revenue, earnings per share and valuation.
Table 2 has AgeX Therapeutics Inc. and XBiotech Inc.’s net margins, return on assets and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|AgeX Therapeutics Inc.||-675.32%||-82%||-63.9%|
AgeX Therapeutics Inc.’s Current Ratio is 3.2 while its Quick Ratio is 3.2. On the competitive side is, XBiotech Inc. which has a 4.6 Current Ratio and a 4.6 Quick Ratio. XBiotech Inc. is better positioned to pay off short and long-term obligations compared to AgeX Therapeutics Inc.
The table delivered features the ratings and recommendations for AgeX Therapeutics Inc. and XBiotech Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|AgeX Therapeutics Inc.||0||0||0||0.00|
On the other hand, XBiotech Inc.’s potential upside is 73.33% and its consensus price target is $13.
Insider and Institutional Ownership
AgeX Therapeutics Inc. and XBiotech Inc. has shares held by institutional investors as follows: 23.8% and 13.5%. About 43.8% of AgeX Therapeutics Inc.’s share are held by insiders. Competitively, 37.8% are XBiotech Inc.’s share held by insiders.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|AgeX Therapeutics Inc.||0.44%||2.24%||11.22%||0%||0%||52.51%|
For the past year AgeX Therapeutics Inc.’s stock price has smaller growth than XBiotech Inc.
XBiotech Inc. beats on 6 of the 10 factors AgeX Therapeutics Inc.
XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.